Abstract
BackgroundAnti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus.MethodsA systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran’s Q test and I2 statistic. Pooled estimates of treatment outcomes were computed using the random effect model.ResultsBased on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4–68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0–16.2%) of the patients died, 14.2% (95% CI: 11.6–16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6–9.7%) failed therapy. Overall 35.4% (95% CI: 30–40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32–54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens.ConclusionThis study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.
Highlights
Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide
We identified a total of 203 original articles, from the initial computer-based search, in the databases PubMed®, Health InterNetwork Access to Research Initiative (Hinari), and Google Scholar
The 14 remaining articles were used for the meta-analysis, including a total study population of 5047 patients from eight high-burden multidrug-resistant tuberculosis (MDR-TB) countries, namely Peru, Latvia, Estonia, Russia, the Philippines, India, South Africa, and Uzbekistan
Summary
Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. It is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus. Anti-tuberculosis (TB) drug resistance is a major public health problem, which threatens the progress made in the control of TB worldwide. In 1999, the Green Light Committee (GLC), a partner of the World Health Organization (WHO), launched the “directly observed treatment, short-course (DOTS)-Plus for MDR-TB” programs for patients with MDR-TB. By the end of 2006, more than 50 DOTS-Plus pilot programs had been launched by GLC, and more than 20 000 patients with MDR-TB were under treatment [2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
